These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12589392)

  • 1. Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance.
    Müller-Vahl KR; Prevedel H; Theloe K; Kolbe H; Emrich HM; Schneider U
    Neuropsychopharmacology; 2003 Feb; 28(2):384-8. PubMed ID: 12589392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance.
    Müller-Vahl KR; Koblenz A; Jöbges M; Kolbe H; Emrich HM; Schneider U
    Pharmacopsychiatry; 2001 Jan; 34(1):19-24. PubMed ID: 11229617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial.
    Müller-Vahl KR; Schneider U; Koblenz A; Jöbges M; Kolbe H; Daldrup T; Emrich HM
    Pharmacopsychiatry; 2002 Mar; 35(2):57-61. PubMed ID: 11951146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial.
    Müller-Vahl KR; Schneider U; Prevedel H; Theloe K; Kolbe H; Daldrup T; Emrich HM
    J Clin Psychiatry; 2003 Apr; 64(4):459-65. PubMed ID: 12716250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marijuana withdrawal in humans: effects of oral THC or divalproex.
    Haney M; Hart CL; Vosburg SK; Nasser J; Bennett A; Zubaran C; Foltin RW
    Neuropsychopharmacology; 2004 Jan; 29(1):158-70. PubMed ID: 14560320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tourette's syndrome.
    Müller-Vahl KR
    Curr Top Behav Neurosci; 2009; 1():397-410. PubMed ID: 21104394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tetrahydrocannabinol (THC) impairs encoding but not retrieval of verbal information.
    Ranganathan M; Radhakrishnan R; Addy PH; Schnakenberg-Martin AM; Williams AH; Carbuto M; Elander J; Pittman B; Andrew Sewell R; Skosnik PD; D'Souza DC
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):176-183. PubMed ID: 28642081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Tourette syndrome with cannabinoids.
    Müller-Vahl KR
    Behav Neurol; 2013; 27(1):119-24. PubMed ID: 23187140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guanfacine Attenuates Adverse Effects of Dronabinol (THC) on Working Memory in Adolescent-Onset Heavy Cannabis Users: A Pilot Study.
    Mathai DS; Holst M; Rodgman C; Haile CN; Keller J; Hussain MZ; Kosten TR; Newton TF; Verrico CD
    J Neuropsychiatry Clin Neurosci; 2018; 30(1):66-76. PubMed ID: 28641496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users.
    Curran HV; Brignell C; Fletcher S; Middleton P; Henry J
    Psychopharmacology (Berl); 2002 Oct; 164(1):61-70. PubMed ID: 12373420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.
    D'Souza DC; Abi-Saab WM; Madonick S; Forselius-Bielen K; Doersch A; Braley G; Gueorguieva R; Cooper TB; Krystal JH
    Biol Psychiatry; 2005 Mar; 57(6):594-608. PubMed ID: 15780846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis.
    D'Souza DC; Perry E; MacDougall L; Ammerman Y; Cooper T; Wu YT; Braley G; Gueorguieva R; Krystal JH
    Neuropsychopharmacology; 2004 Aug; 29(8):1558-72. PubMed ID: 15173844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans.
    D'Souza DC; Braley G; Blaise R; Vendetti M; Oliver S; Pittman B; Ranganathan M; Bhakta S; Zimolo Z; Cooper T; Perry E
    Psychopharmacology (Berl); 2008 Jul; 198(4):587-603. PubMed ID: 18228005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different responses of repetitive behaviours in juvenile and young adult mice to Δ
    Gorberg V; McCaffery P; Anavi-Goffer S
    Br J Pharmacol; 2021 Feb; 178(3):614-625. PubMed ID: 33125731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users.
    Ramaekers JG; Kauert G; Theunissen EL; Toennes SW; Moeller MR
    J Psychopharmacol; 2009 May; 23(3):266-77. PubMed ID: 18719045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre- and post-conditioning treatment with an ultra-low dose of Δ9-tetrahydrocannabinol (THC) protects against pentylenetetrazole (PTZ)-induced cognitive damage.
    Assaf F; Fishbein M; Gafni M; Keren O; Sarne Y
    Behav Brain Res; 2011 Jun; 220(1):194-201. PubMed ID: 21315768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabis with high δ9-THC contents affects perception and visual selective attention acutely: an event-related potential study.
    Böcker KB; Gerritsen J; Hunault CC; Kruidenier M; Mensinga TT; Kenemans JL
    Pharmacol Biochem Behav; 2010 Jul; 96(1):67-74. PubMed ID: 20417659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pure delta-9-tetrahydrocannabinol and its combination with cannabidiol in treatment-resistant Tourette syndrome: A case report.
    Pichler EM; Kawohl W; Seifritz E; Roser P
    Int J Psychiatry Med; 2019 Mar; 54(2):150-156. PubMed ID: 30058466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabinoids reduce symptoms of Tourette's syndrome.
    Müller-Vahl KR
    Expert Opin Pharmacother; 2003 Oct; 4(10):1717-25. PubMed ID: 14521482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group.
    ; Strasser F; Luftner D; Possinger K; Ernst G; Ruhstaller T; Meissner W; Ko YD; Schnelle M; Reif M; Cerny T
    J Clin Oncol; 2006 Jul; 24(21):3394-400. PubMed ID: 16849753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.